Evidence map›Paper›PMID 42529376›Full record

ReviewFrontiers in bioengineering and biotechnology2026

Extracellular vesicle-based delivery to airway basal cells for durable gene therapy in cystic fibrosis.

Anastasiia Ivleva, Anna Demchenko, Svetlana Smirnikhina

Abstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anastasiia IvlevaLaboratory of Genome Editing, Research Centre for Medical Genetics, Moscow, Russia.
Anna DemchenkoLaboratory of Genome Editing, Research Centre for Medical Genetics, Moscow, Russia.
Svetlana SmirnikhinaLaboratory of Genome Editing, Research Centre for Medical Genetics, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Airway basal cells are an appealing target for durable genetic therapy in cystic fibrosis because they are long-lived stem/progenitor cells that maintain and regenerate the pseudostratified airway epithelium. Correcting this compartment could, in principle, enable sustained restoration of CFTR function in differentiated epithelial lineages. However, selective

Indexed as

airway basal cellscystic fibrosisextracellular vesiclesgene therapypeptide ligandssurface markerstargeted delivery

Identifiers

PMID42529376
PMCPMC13416855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.